Silk Road Medical Inc

Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Silk Road Medical Inc reports robust Q4 performance and eyes global expansion

Silk Road Medical Inc's Q4 2022 performance reflects strong revenue growth and operational efficiency, supported by a focus on market expansion and cost management.
While facing challenges in cost control and operational metrics, the company's strategic initiatives and revenue guidance for 2023 signal growth potential.
Opportunities lie in leveraging the cash balance for growth, expanding TCAR utilization, and addressing analyst concerns to drive future success.

Silk Road Medical reports robust Q1 earnings and eyes international expansion

Silk Road Medical's Q1 2023 earnings call highlighted strong revenue growth, innovative product launches, and strategic international expansion plans.
While the company faces challenges in scaling operations and managing costs, it remains well-positioned with a solid financial foundation and a focus on driving sustainable growth.
With a clear focus on optimizing revenue per procedure and expanding geographically, Silk Road Medical is poised to capitalize on opportunities for market growth and product adoption.

Silk Road Medical Inc posts strong Q2 earnings, eyes global expansion

Silk Road Medical Inc delivered robust Q2 2023 results, showcasing revenue growth, product advancements, and strategic progress. While facing competition and regulatory challenges, the company is well-positioned to capitalize on international markets and drive further growth through operational efficiency.

Silk Road Medical posts strong Q3 results, eyes growth opportunities

Silk Road Medical's Q3 2023 earnings call highlighted robust financial performance, leadership changes, strategic initiatives, and market opportunities. The company faces challenges in sales force management and margin optimization but is well-positioned to capitalize on growth prospects.

Silk Road Medical reports robust 2023 earnings, eyes international expansion

Silk Road Medical's strong financial performance in 2023, driven by revenue growth and strategic initiatives, sets the stage for continued success.
While facing challenges such as sales force turnover and market dynamics, the company's focus on innovation and international expansion presents opportunities for growth.
Maintaining a stable pricing strategy, deepening physician adoption, and leveraging new product advancements are key to Silk Road's sustainable growth strategy.
Navigating competition in carotid treatments and maximizing the adoption curve for TCAR procedures are critical areas for Silk Road's future success.

Silk Road Medical reports robust Q1 earnings and eyes international growth

Silk Road Medical's Q1 2024 performance reflects revenue growth, improved EBITDA, and strong financial stability despite operational challenges.
The company's strengths lie in its leadership in carotid treatment, growth opportunities in international markets, and innovative product development.
Challenges include profitability concerns, margin pressure, and the need for efficient cost management amid rising expenses.
Opportunities for Silk Road Medical include market expansion, revenue growth, and continued innovation to solidify its position as a leader in carotid treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

SUNNYVALE, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

Silk Road Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference

Cardinal Health

Olink Holding AB

Neuronetics Inc

Transmedics Group Inc

Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.

5 Winning Medical Product Stocks That Still Have Room to Run

Does Silk Road Medical (SILK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Silk Road Medical (SILK) is a Great Momentum Stock: Should You Buy?

Revenue growth of 51% YoY to $37.4mm was driven by a corresponding 55% YoY gain in TCAR procedural volume. management raised FY22 revenue guidance to $137mm at the top of range.

Silk Road Medical: Revise To Buy As TCAR Procedural Volume Ramps Up

Silk Road Medical, Inc. (NASDAQ:SILK ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Marissa Bych - IR Erica Rogers - President & CEO Lucas Buchanan - CFO & Chief Operating Officer Conference Call Participants Rick Wise - Stifel Adam Maeder - Piper Sandler Operator Good day, and thank you for standing by. Welcome to the Silk Road Medical 2022 Third Quarter Earnings Conference Call.

Silk Road Medical, Inc. (SILK) Q3 2022 Earnings Call Transcript

Silk Road Medical (SILK) delivered earnings and revenue surprises of 34.09% and 10.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Reports Q3 Loss, Tops Revenue Estimates

SUNNYVALE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) --  Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that management will present at the following investor conferences.

Silk Road Medical to Present at Upcoming Investor Conferences

SUNNYVALE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2022 after market close on Tuesday, November 8th, 2022. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report Third Quarter 2022 Financial Results on November 8, 2022

Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Silk Road Medical (SILK) Stock Jumps 6.7%: Will It Continue to Soar?

SUNNYVALE, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the pricing of an underwritten public offering of 2,325,582 shares of its common stock at a public offering price of $43.00 per share, before deducting underwriting discounts and commissions. In addition, Silk Road Medical has granted the underwriters a 30-day option to purchase up to an additional 348,837 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering to Silk Road Medical are expected to be approximately $100.0 million. The offering is expected to close on October 21, 2022, subject to the satisfaction of customary closing conditions.

Silk Road Medical Announces Pricing of Public Offering

SUNNYVALE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced certain preliminary financial data for the quarter ended September 30, 2022.

Silk Road Medical Announces Certain Preliminary Financial Data For Quarter Ended September 30, 2022

SUNNYVALE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, announced today the commencement of a proposed underwritten public offering of $100 million of shares of its common stock.  In addition, Silk Road Medical expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount of up to 15% of the number of shares sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Silk Road Medical Announces Proposed Public Offering of Common Stock

Silk Road Medical (SILK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Silk Road Medical (SILK): Can Its 9.3% Jump Turn into More Strength?

SUNNYVALE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced enrollment of the first patient in ROADSTER 3, the first prospective, multi-center, single-arm study to assess real-world treatment of standard surgical risk (SSR) patients with carotid artery disease using TCAR. The procedure was performed by Dr. Animesh Rathore at Sentara Norfolk General Hospital in Norfolk, VA.

Silk Road Medical Announces First Patient Enrolled in ROADSTER 3 Post Approval Study Evaluating TCAR® System in the Treatment of Standard Surgical Risk Patients

SUNNYVALE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming Morgan Stanley 20th Annual Global Healthcare Conference held in New York, New York.

Silk Road Medical to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Silk Road Medical, Inc. (NASDAQ:SILK ) Q2 2022 Earnings Conference Call July 26, 2022 4:30 PM ET Company Participants Marissa Bych - Investor Relations Erica Rogers - President and Chief Executive Officer Lucas Buchanan - Chief Financial Officer and Chief Operating Officer Conference Call Participants Lily Baik - J.P. Morgan Rick Wise - Stifel Mike Polark - Wolfe Research Anthony Pettinari - Citi Adam Maeder - Piper Sandler Operator Ladies and gentlemen, thank you for standingby, and welcome to Silk Road Medical's 2022 Second Quarter Earnings Conference Call.

Silk Road Medical, Inc. (SILK) CEO Erica Rogers on Q2 2022 Results - Earnings Call Transcript

SUNNYVALE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2022.

Silk Road Medical Reports Second Quarter 2022 Financial Results

SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the second quarter 2022 after market close on Tuesday, July 26, 2022. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report Second Quarter 2022 Financial Results on July 26, 2022

SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) --  Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced a prospective study to evaluate the TCAR® system in the treatment of standard surgical risk patients with carotid artery disease. The post-market study, called ROADSTER 3, will fulfill the U.S. Food and Drug Administration's (FDA) condition of approval for the recent expansion of labeling for the ENROUTE® Transcarotid Stent System, which now includes patients at high and standard risk of complications from carotid endarterectomy (CEA).

Silk Road Medical Announces Post Approval Study for the Treatment of Standard Surgical Risk Patients using TCAR

SUNNYVALE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that the Centers for Medicare and Medicaid Services (CMS), through collaboration with the Society of Vascular Surgery's Patient Safety Organization (SVS PSO) and their Vascular Quality Initiative (VQI), has expanded coverage for TCAR to include standard surgical risk patients within the VQI's TCAR Surveillance Project (TSP). This decision is effective immediately and comes on the heels of the recent Food and Drug Administration (FDA) approval for expanded indications for the ENROUTE® Transcarotid Stent System to include patients at high risk and standard risk for adverse events from carotid endarterectomy (CEA).

Silk Road Medical Announces Expanded Medicare Coverage for TCAR in Standard Surgical Risk Patients

SUNNYVALE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Company) (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has entered into a new five-year loan arrangement with Oxford Finance LLC (Oxford) comprising up to a $200 million term loan and up to a $50 million revolving line of credit. The transaction brings the Company's total cash, cash equivalents, and access to liquidity to approximately $340 million.

Silk Road Medical Extends Cash Runway by Securing up to $250 Million in Debt Financing

Abercrombie & Fitch

Cheesecake Factory

In a year in which the risk-on trade has been muted, U.S. small cap stocks are holding up relatively well. In fact, the historically more volatile asset class is down approximately 13% year-to-date compared to 15% for U.S. large caps

3 Small Caps With Big Return Potential

Silk Road Medical, Inc. (NASDAQ:SILK ) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Erica Rogers - CEO Lucas Buchanan - CFO Conference Call Participants Adam Maeder - Piper Sandler Danielle Antalffy - SVB Securities Javier Fonseca - Spartan Capital Rick Wise – Stifel Michael Polark - Wolfe Research Marissa Bych - Gilmartin Group Operator Good afternoon, and welcome to Silk Road Medical's First Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Silk Road Medical, Inc. (SILK) CEO Erica Rogers on Q1 2022 Results - Earnings Call Transcript

Silk Road Medical (SILK) delivered earnings and revenue surprises of -17.07% and 5.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Reports Q1 Loss, Tops Revenue Estimates

SUNNYVALE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2022.

News for Silk Road Medical Inc Stock (SILK)